Logo image of MRUS

MERUS NV (MRUS) Stock Fundamental Analysis

USA - NASDAQ:MRUS - NL0011606264 - Common Stock

94.38 USD
-0.01 (-0.01%)
Last: 10/8/2025, 8:02:13 PM
94.38 USD
0 (0%)
After Hours: 10/8/2025, 8:02:13 PM
Fundamental Rating

4

Taking everything into account, MRUS scores 4 out of 10 in our fundamental rating. MRUS was compared to 536 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MRUS as it has an excellent financial health rating, but there are worries on the profitability. MRUS is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

MRUS had negative earnings in the past year.
MRUS had a negative operating cash flow in the past year.
In the past 5 years MRUS always reported negative net income.
In the past 5 years MRUS always reported negative operating cash flow.
MRUS Yearly Net Income VS EBIT VS OCF VS FCFMRUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M -250M

1.2 Ratios

The Return On Assets of MRUS (-39.33%) is better than 60.45% of its industry peers.
With a decent Return On Equity value of -45.80%, MRUS is doing good in the industry, outperforming 68.84% of the companies in the same industry.
Industry RankSector Rank
ROA -39.33%
ROE -45.8%
ROIC N/A
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.9%
ROIC(3y)N/A
ROIC(5y)N/A
MRUS Yearly ROA, ROE, ROICMRUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100

1.3 Margins

MRUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MRUS Yearly Profit, Operating, Gross MarginsMRUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

MRUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MRUS has been increased compared to 1 year ago.
The number of shares outstanding for MRUS has been increased compared to 5 years ago.
MRUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MRUS Yearly Shares OutstandingMRUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
MRUS Yearly Total Debt VS Total AssetsMRUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

MRUS has an Altman-Z score of 28.97. This indicates that MRUS is financially healthy and has little risk of bankruptcy at the moment.
MRUS has a better Altman-Z score (28.97) than 94.59% of its industry peers.
There is no outstanding debt for MRUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 28.97
ROIC/WACCN/A
WACC7.52%
MRUS Yearly LT Debt VS Equity VS FCFMRUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

MRUS has a Current Ratio of 8.39. This indicates that MRUS is financially healthy and has no problem in meeting its short term obligations.
MRUS has a Current ratio of 8.39. This is in the better half of the industry: MRUS outperforms 74.63% of its industry peers.
A Quick Ratio of 8.39 indicates that MRUS has no problem at all paying its short term obligations.
MRUS has a Quick ratio of 8.39. This is in the better half of the industry: MRUS outperforms 74.81% of its industry peers.
Industry RankSector Rank
Current Ratio 8.39
Quick Ratio 8.39
MRUS Yearly Current Assets VS Current LiabilitesMRUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

6

3. Growth

3.1 Past

MRUS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -93.03%.
Looking at the last year, MRUS shows a very strong growth in Revenue. The Revenue has grown by 59.78%.
Measured over the past years, MRUS shows a small growth in Revenue. The Revenue has been growing by 3.03% on average per year.
EPS 1Y (TTM)-93.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-175.31%
Revenue 1Y (TTM)59.78%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%20.4%

3.2 Future

The Earnings Per Share is expected to grow by 29.39% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 93.28% on average over the next years. This is a very strong growth
EPS Next Y-84.27%
EPS Next 2Y-27.66%
EPS Next 3Y-11.65%
EPS Next 5Y29.39%
Revenue Next Year35.25%
Revenue Next 2Y15.87%
Revenue Next 3Y65.71%
Revenue Next 5Y93.28%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
MRUS Yearly Revenue VS EstimatesMRUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
MRUS Yearly EPS VS EstimatesMRUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 -5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

MRUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MRUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MRUS Price Earnings VS Forward Price EarningsMRUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MRUS Per share dataMRUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10

4.3 Compensation for Growth

MRUS's earnings are expected to decrease with -11.65% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-27.66%
EPS Next 3Y-11.65%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MRUS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MERUS NV

NASDAQ:MRUS (10/8/2025, 8:02:13 PM)

After market: 94.38 0 (0%)

94.38

-0.01 (-0.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-05 2025-08-05/amc
Earnings (Next)10-30 2025-10-30/amc
Inst Owners101.95%
Inst Owner Change0%
Ins Owners0.37%
Ins Owner Change0.73%
Market Cap7.15B
Analysts72.17
Price Target94.52 (0.15%)
Short Float %5.92%
Short Ratio3.16
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-55.78%
Min EPS beat(2)-83.38%
Max EPS beat(2)-28.18%
EPS beat(4)1
Avg EPS beat(4)-30.51%
Min EPS beat(4)-83.38%
Max EPS beat(4)51.7%
EPS beat(8)3
Avg EPS beat(8)-11.64%
EPS beat(12)6
Avg EPS beat(12)-12.33%
EPS beat(16)10
Avg EPS beat(16)3.02%
Revenue beat(2)1
Avg Revenue beat(2)97.51%
Min Revenue beat(2)-37.2%
Max Revenue beat(2)232.22%
Revenue beat(4)2
Avg Revenue beat(4)58.34%
Min Revenue beat(4)-37.2%
Max Revenue beat(4)232.22%
Revenue beat(8)3
Avg Revenue beat(8)23.48%
Revenue beat(12)5
Avg Revenue beat(12)13.5%
Revenue beat(16)9
Avg Revenue beat(16)14.23%
PT rev (1m)1.14%
PT rev (3m)1.69%
EPS NQ rev (1m)-1.57%
EPS NQ rev (3m)-17.92%
EPS NY rev (1m)-0.4%
EPS NY rev (3m)-22.76%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-13.85%
Revenue NY rev (1m)-6.46%
Revenue NY rev (3m)-16.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 127.2
P/FCF N/A
P/OCF N/A
P/B 8.5
P/tB 8.52
EV/EBITDA N/A
EPS(TTM)-5.54
EYN/A
EPS(NY)-5.39
Fwd EYN/A
FCF(TTM)-4.13
FCFYN/A
OCF(TTM)-4.13
OCFYN/A
SpS0.74
BVpS11.11
TBVpS11.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -39.33%
ROE -45.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.12%
ROA(5y)-29.6%
ROE(3y)-43.27%
ROE(5y)-46.9%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.06
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 22.54%
Cap/Sales 0.98%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.39
Quick Ratio 8.39
Altman-Z 28.97
F-Score3
WACC7.52%
ROIC/WACCN/A
Cap/Depr(3y)275.9%
Cap/Depr(5y)195.01%
Cap/Sales(3y)10.83%
Cap/Sales(5y)7.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-93.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-175.31%
EPS Next Y-84.27%
EPS Next 2Y-27.66%
EPS Next 3Y-11.65%
EPS Next 5Y29.39%
Revenue 1Y (TTM)59.78%
Revenue growth 3Y-9.72%
Revenue growth 5Y3.03%
Sales Q2Q%20.4%
Revenue Next Year35.25%
Revenue Next 2Y15.87%
Revenue Next 3Y65.71%
Revenue Next 5Y93.28%
EBIT growth 1Y-76.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-48.71%
EBIT Next 3Y8.11%
EBIT Next 5YN/A
FCF growth 1Y-97.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-108.38%
OCF growth 3YN/A
OCF growth 5YN/A